Solna on
The Nomination Committee for the 2022 Annual General Meeting comprises the following members:
- Per Arwidsson, appointed by
Arwidsro Investment AB , - Håkan Lagerberg, appointed by
Mastan AB , and - Anders Härfstrand, Chairman of the
Board of Oasmia .
Per Arwidsson has been appointed Chairman of the Nomination Committee.
Oasmia’s Annual General Meeting will be held on
Shareholders who wish to submit proposals to the Nomination Committee for the 2022 Annual General Meeting may send them by e-mail to nomination@oasmia.com. In order for the Nomination Committee to be able to consider submitted proposals in a constructive manner, these should be submitted well in advance of the Annual General Meeting.
For more information:
Anders Härfstrand, Chairman of the
Phone: 018-50 54 40
E-mail: IR@oasmia.com
About
Oasmia is a specialty pharmaceutical company focused on the development of new therapeutic options for patients suffering from hard-to-treat cancers. It has a growing pipeline of clinical-stage assets targeting late-stage cancers. Apealea® (paclitaxel micellar) is being made available to ovarian cancer patients through a partnership with
© Modular Finance, source